Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of MGCD265 in MET-altered Advanced NSCLC
2015-002070-21Phase 2Completed
- Sponsor
- Mirati Therapeutics
- Start
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of glesatinib in non-small cell lung cancer (NSCLC), sponsored by Mirati Therapeutics. Primary endpoint: Objective Response Rate (ORR). Started Sep 2015; status: completed.
02
Drugs
glesatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2015-002070-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002070-21.